Načítá se...
Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune‐related adverse events (irAEs). Pneumonitis is an uncommon but...
Uloženo v:
| Vydáno v: | Thorac Cancer |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons Australia, Ltd
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8169295/ https://ncbi.nlm.nih.gov/pubmed/33949137 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13967 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|